Synageva BioPharma 8-K Submission of Matters to a Vote of Security Holders

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 6, 2013

SYNAGEVA BIOPHARMA CORP.

(Exact Name of Registrant as Specified in Charter)

Delaware	0-23155	56-1808663
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

33 Hayden Ave., Lexington, Massachusetts 02421

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 357-9900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

The annual meeting of stockholders of Synageva BioPharma Corp. (the “Company”) was held on June 6, 2013. Only stockholders of record as of April 12, 2013 (the “Record Date”) were entitled to vote at the annual meeting. As of the Record Date, there were 27,264,039 shares outstanding and entitled to vote at the annual meeting, of which 26,651,449 shares were represented by proxy, constituting a quorum on all matters voted upon. The stockholders voted on the following matters:

Proposal 1: Stockholders elected each nominee for director, each to serve until the next annual meeting of stockholders or until his successor is duly elected and qualified:

Name	For		Withheld		Broker Non-Votes
Felix J. Baker		25,893,311		426,026		332,112
Stephen R. Biggar		25,988,469		330,868		332,112
Stephen R. Davis		26,255,199		64,138		332,112
Thomas R. Malley		26,286,012		33,325		332,112
Barry Quart		26,261,814		57,523		332,112
Sanj K. Patel		26,108,421		210,916		332,112
Thomas J. Tisch		26,292,867		26,470		332,112
Peter Wirth		26,260,799		58,538		332,112

Proposal 2: Stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers:

For	Against	Abstaining	Broker Non-Votes
24,692,577	1,623,006	3,754	332,112

Proposal 3: Stockholders recommended, on a non-binding advisory basis, that future advisory votes to approve executive compensation be held once every year:

One Year	Two Years	Three Years	Abstaining	Broker Non-Votes
25,507,371	2,710	806,759	2,497	332,112

Based on the results of this vote, the Company will implement an annual advisory vote on executive compensation until the next vote on frequency.

Proposal 4: Stockholders approved amendments to the Company’s 2005 Stock Plan to increase the number of shares of common stock available for issuance by 1,500,000 million shares (subject to adjustment in the event of stock splits and other similar events):

For	Against	Abstaining	Broker Non-Votes
25,981,493	336,024	1,820	332,112

Proposal 5: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013:

For	Against	Abstaining
26,648,040	2,920	489

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SYNAGEVA BIOPHARMA CORP.
By:	/s/ Sanj K. Patel
	Sanj K. Patel
	President and Chief Executive Officer

Date: June 10, 2013